Tumor biomarker CA724 (also known as Tumor-associated glycoprotein 72, TAG-72) was suggested for the management of gastrointestinal and gynecological cancers as early as two decades previously; [27–29] however, the reason for a potential association between serum biomarker CA724 and HER2 overexpression is interesting but lacks relevant investigations. The gene discussed is ERBB2; the disease is neoplasm.